Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6058812 | 0.90 | BACE1 (0.42) | TDP1MAPTMEN1KMT2APOLB | |
| SCHEMBL5528639 | 0.83 | BACE1 (0.38) | TDP1MAPTMEN1KMT2APOLB | |
| SCHEMBL28128897 | 0.81 | GPR35 (0.58) | TDP1MAPTMEN1KMT2APOLB | |
| SCHEMBL6059195 | 0.74 | USP7 (0.37) | — | |
| SCHEMBL6058698 | 0.74 | BACE1 (0.34) | TDP1MAPTPOLBBACE1ALDH1A1 | |
| SCHEMBL1372762 | 0.73 | GPR35 (0.40) | TDP1MAPTMEN1KMT2APOLB | |
| SCHEMBL4588943 | 0.72 | TDP1 (0.58) | TDP1MAPTMEN1KMT2APOLB | |
| SCHEMBL27815805 | 0.72 | GPR35 (0.52) | TDP1MAPTMEN1KMT2APOLB | |
| SCHEMBL572190 | 0.72 | TDP1 (0.58) | TDP1MAPTMEN1KMT2APOLB | |
| SCHEMBL6701790 | 0.71 | ESR1 (0.46) | KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0877607-B1 | BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS | AVENTIS PHARMA SA (FR) | 2006-11-15 | — | — | EP | disclosed |
| US-6794415-B2 | Biphenyl compounds and their use as oestrogenic agents | AVENTIS PHARMA S.A. (FR) | 2004-09-21 | — | — | US | disclosed |
| US-20040043993-A1 | Biphenyl compounds and their use as oestrogenic agents | AVENTIS PHARMA S.A. | 2004-03-04 | — | — | US | disclosed |
| US-6563008-B2 | Treatment of disorders linked to hypofolliculinemia and of certain estrogen-dependent pathologies such as prostatic adenomas or carcinomas, and of benign tumours of the breast | AVENTIS PHARMA S.A. (FR) | 2003-05-13 | — | — | US | disclosed |
| US-20020068736-A1 | Biphenyl compounds and their use as oestrogenic agents | LESUISSE DOMINIQUE (FR) | 2002-06-06 | — | — | US | disclosed |
| US-6288126-B1 | Biphenyl compounds and use thereof as oestrogenic agents | AVENTIS PHARMA S.A. | 2001-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068736-A1 | Biphenyl compounds and their use as oestrogenic agents | ESR2, ESR1, CYP19A1 | TDP1 4524/4885MAPT 4496/4885MEN1 1831/4885 |
| US-20040043993-A1 | Biphenyl compounds and their use as oestrogenic agents | CYP19A1, HSD17B11, GPER1 | TDP1 3945/4885MAPT 4418/4885MEN1 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.